Moderna says its experimental mRNA influenza vaccine, mRNA-1010, showed more than 30% greater relative vaccine efficacy ...

A potential massive breakthrough!

By Deanna Neff HealthDay ReporterTHURSDAY, Feb. 19, 2026 (HealthDay News) — In a sudden reversal, the U.S. Food and Drug Administration (FDA) has agreed to review Moderna’s experimental mRNA influenza ...

“mRNA vaccine technology has fundamentally changed our ability to respond quickly and precisely to emerging viral threats,” said Johan Neyts, PhD, Director of the GVN Center of Excellence at KU Leuven ...

The Global Virus Network (GVN), a coalition of leading human and animal virologists from 80+ Centers of Excellence and Affiliates in more than 40 countries dedicated to advancing pandemic preparedness ...

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

Therapeutic vaccines are advancing in oncology and HIV, with the aim of retraining immune responses to target tumors and persistent viral reservoirs with precision.

In a major blow to vaccine development, the FDA said it will not review Moderna’s application for the first mRNA-based flu shot.

A consortium including Korea Disease Control and Prevention Agency (KDCA), International Vaccine Institute (IVI), ST Pharm Co. Ltd. and Seoul National University (SNU) is joining forces with CEPI to ...

Add Yahoo as a preferred source to see more of our stories on Google. Health and Human Services Secretary Robert F. Kennedy Jr. canceled $500 million of funding for research on mRNA vaccine technology ...